Browse by Medical Category
Research at Mass General
Call the center
The psychiatrists and psychologists on staff in the Center for Anxiety and Traumatic Stress Disorders (CATSD) and Complicated Grief Program at Massachusetts General Hospital explore the causes and treatments for a variety of anxiety-related disorders and seek to also learn more about the underlying causes and course of these disorders.
The research studies conducted by the CATSD provide the opportunity for staff and patients to work together on identifying and developing new treatment methods for these anxiety-related disorders.
Our psychiatrists and psychologists draw on years of experience and are focused on treating and conducting extensive research.
We work on a variety of anxiety disorders through our treatment and research program. Learn more about our program's approach to each of those disorders here:
The Center for Anxiety and Traumatic Stress Disorders and Complicated Grief Program conducts research on post-traumatic stress disorder, complicated grief disorder, panic disorder, generalized anxiety disorder and social anxiety disorder.
To learn more about enrolling in our research, please contact us by phone (617-726-6944) or email (firstname.lastname@example.org).
Description: The purpose of this study is to compare the effects of mindfulness-based stress reduction (MBSR) with Lexapro (escitalopram) to see how they compare for treating anxiety disorders. MBSR is a class that instructs participants in the theory and practice of several forms of mindfulness meditation. Escitalopram (Lexapro) is an antidepressant medication that is FDA-approved for the treatment of generalized anxiety disorder and depression. It is commonly used in practice for other anxiety disorders.
This research is being done because there is a need for more information about the comparison of treatments to be able to make informed decisions about health care for disorders. Although mindfulness meditation is gaining popularity, there is no information how this treatment strategy compares with standard treatment, such as medication, for anxiety disorders.
If you are interested in participating in or learning more about this research study, please email us at email@example.com or call 1-866-44-WORRY.
Compensation: May be available for eligible participants
Study Sponsor: Department of Defense
Description: The purpose of this research study is to see whether Losartan, an FDA-approved medication that is commonly prescribed for the treatment of high blood pressure, may be effective for treating Post-traumatic Stress Disorder (PTSD). After medical and psychiatric evaluations are completed, eligible participants are randomly assigned (that is, by chance) to one of two study medications lasting approximately 12 weeks: Losartan or Placebo (a sugar pill without active medication).
Compensation: Participants will be paid $25 upon completion of the intake visit, as well as $25 for each of 7 study assessment visits, for a maximum total of $200.
Description: We are is seeking adult participants who experienced the death of a loved one more than six months ago for a study of bereavement. The aim of this study is to learn more about how people adjust to the death of a loved one. Specifically, we hope to investigate the psychological and biological mechanisms that lead grief to persist for some bereaved adults but not others. The study will last approximately 2.5 weeks and will require two in-person visits to our clinic. Additionally, you will be asked to complete daily surveys on your phone. All collected information will remain strictly confidential.
You may be eligible if:
Please call our phone screen line at 1-866-44-WORRY (866-449-6779) or email us at firstname.lastname@example.org for a full phone screen to determine if you would be eligible to come into the clinic to meet with one of the study doctors.
Compensation: Eligible participants would receive up to $250 in compensation.
Description: The purpose of this research study is to examine how symptoms of panic disorder change during cognitive behavioral therapy (CBT) for panic disorder. The aim of this type of research is to focus on the symptoms and experiences of each person through the course of treatment, in order to develop a framework for a personalized medicine approach to treating panic disorder. All participants will receive seven sessions of CBT.
Please call our phone screen line at 866-44-WORRY (866-449-6779) or email us at email@example.com for a full phone screen to determine if you would be eligible to come into the clinic to meet with one of the study doctors.
We are not currently conducting any studies for generalized anxiety disorder. Please check back soon for updates.
We are not currently conducting any studies for social anxiety disorder. Please check back soon for updates.
Interim DirectorPsychiatrist-in-Chief, Massachusetts General Hospital Stanley Cobb Professor of Psychiatry, Harvard Medical School
Dr. Jerrold Rosenbaum is recognized as one of the world’s authorities on mood and anxiety disorders, with a special emphasis on pharmacotherapy of those conditions. His research contributions include extensive leadership in the development of new therapies, the design and implementation of trials to develop innovative treatments for major depression, treatment resistant depression, and panic disorder, studies of psychopathology including comorbidity and subtypes, and studies of longitudinal course and outcomes of those disorders.
Dr. Rosenbaum has authored more than 400 original articles and reviews and has authored or edited 20 books. He currently serves on 12 editorial boards of professional journals or newsletters. A particular research focus has been ongoing studies of children at risk for anxiety disorders and depression, which examine behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure and function of children of parents with mood and anxiety disorders.
At Mass General, Dr. Rosenbaum directs a department of more than 600 clinicians, researchers and trainees. He has also served as chair of the hospital’s Executive Committee on Research. His clinical and consulting practice specializes in treatment resistant mood and anxiety disorders, and he consults extensively to colleagues on management of these conditions.
See Dr. Rosenbaum's publications.
Associate DirectorDirector of Research, Center for Anxiety and Traumatic Stress Disorders and Complicated Grief ProgramDirector, Community Psychiatry Program for Research in Implementation and Dissemination of Evidence-Based Treatments (PRIDE)Associate Professor, Harvard Medical School
Dr. Luana Marques is the president-elect of the Anxiety and Depression Association of America (ADAA). She completed her PhD in clinical psychology at the State University of New York (SUNY) at Buffalo and her clinical internship in the Cognitive Behavioral Track (CBT) at Mass General/Harvard Medical School in 2007.
Recognized as a national and international expert in CBT and conducting clinical research in health disparities and trauma-related disorders, Dr. Marques’ major clinical and research interests include the dissemination and implementation of evidence-based practices for individuals suffering from a variety of behavioral health disorders in diverse communities. Upon beginning her work in community mental health clinics, Dr. Marques became increasingly aware of the substantial implementation gap in evidence-based psychotherapeutic treatments for anxiety and trauma-related disorders.
Dr. Marques has worked with community-based organizations and community health clinics to translate evidence-based research into programming and treatments tailored to serve diverse community settings, especially for populations that are Spanish speaking in the United States and in Mexico. Her work with community-based organizations and community health clinics to implement has resulted in sustainable, bidirectional community partnerships, that have helped address the gap between research and practice. Dr. Marques’ goal is to continue working towards decreasing the disparities in care for individuals experiencing behavioral health difficulties, especially among low-income and ethnic minorities.
See Dr. Marques' publications.
Dr. Bui's main research interests include furthering the understanding and treatment of anxiety and stress-related disorders, including both PTSD and the newly defined condition of complicated grief. His research focuses on elucidating the neurobiological and phenomenological bases of these conditions in order to develop novel treatment interventions. He has served as co-investigator on many federally-funded studies and has recently received grants for pilot studies to develop and test novel mind-body interventions with bereavement and stress-related conditions.
Dr. Bui is member of the Anxiety and Depression Association of America, of the Société Française de Psychiatrie de l’Enfant et de l’Adolescent et Disciplines Associées and of the International Society for Traumatic Stress Studies. He received an MD from Toulouse University and completed his residency at Toulouse University Hospital (France). In addition, he worked as faculty at Toulouse University Hospital for three years and completed a PhD in Neuroscience at Toulouse University. He has received various awards as a young investigator, including a travel award from the American College of Neuropsychopharmacology and the Prix Bretesche de Médecine from the Académie des Sciences, Inscriptions, et Belles Lettres de Toulouse.
Publications by Dr. Bui
Dr. Paolo Cassano is assistant professor of psychiatry at Harvard Medical School and director of photobiomodulation at the Center for Anxiety and Traumatic Stress Disorders and the Depression and Clinical Research Program (DCRP).
Dr. Cassano received both his MD in medicine and surgery and his PhD in clinical neuro-psychopharmacology from the University of Pisa in Italy. He pursued postdoctoral studies in mood and anxiety disorders with the DCRP and graduated from the Mass General-McLean Adult Psychiatry Residency Program in 2009 at Harvard University.
Since 2009, Dr. Cassano has led multiple studies on transcranial photobiomodulation with near-infrared light for anxiety and mood disorders, including translational studies aimed at discovering the mechanisms of action of photobiomodulation. His translational studies have focused on the effects of near-infrared light on mitochondria, cerebral blood flow (fNIRs-DCS), on brain electrical activity (EEG) and on autonomic reactivity, such as heart rate variability (HRV). For his studies on photobiomodulation, he was awarded competitive, national grants such as the Brain and Behavior Research Foundation NARSAD. He was also the principal investigator on several multicenter clinical trials, sponsored by private companies, to test photobiomodulation for anxiety and depression.
These groundbreaking projects have led to very promising results; they have demonstrated preliminary efficacy of near-infrared light for the treatment of psychiatric disorders.
Publications by Dr. Cassano
Dr. Devon Hinton is a board-certified psychiatrist and an associate professor of psychiatry at Harvard Medical School. After receiving his MD, Dr. Hinton completed his medical internship and his residency in psychiatry at Harvard Medical School (Longwood program). He also has a PhD in Medical Anthropology from Harvard University. Dr. Hinton’s major clinical and research interests include the culturally sensitive assessment and treatment of PTSD and panic disorder in traumatized refugee and ethnic minority populations. He is fluent in several languages, including Cambodian and Spanish. He has served as a principal investigator on numerous studies examining the phenomenology and treatment of PTSD, panic attacks, and panic disorder in Southeast Asian (Cambodian, Laotian, Vietnamese) and Latino populations. Dr. Hinton has been the Principal Investigator on studies funded by the National Institute of Mental Health on developing culturally sensitive treatment of traumatized refugees.
Dr. Hinton is a member of the DSM-V Cultural Study subgroup and an advisor to the Anxiety, OC, Posttraumatic, and Dissociative Disorders Work Group of DSM–V (American Psychiatric Association). He is the co-editor of the book Culture and Panic Disorder and is the first author on over 100 chapters or original research articles.
Publications by Dr. Hinton
Staff PsychiatristAssistant Professor, Harvard Medical School
Dr. Worthington is a staff psychiatrist at the Center for Anxiety and Traumatic Stress Disorders and Complicated Grief Program and an instructor in psychiatry at Harvard Medical School. He received his MD from Georgetown University School of Medicine in Washington, D.C., completed his residency at the University of North Carolina Hospitals in Chapel Hill, NC and did a research fellowship in Clinical Psychopharmacology at Mass General.
Currently he is an investigator on several National Institutes of Mental Health studies involving the course of treatment-refractory panic disorder, treatment-resistant depression, and the predication of outcome during antidepressant discontinuation. He is also an investigator in numerous phase II and phase III clinical trials sponsored by several pharmaceutical companies. He has published over 150 articles, reviews and posters and he lectures in national and international forums. His areas of clinical interest include the effects of alcohol and substance use on mood and anxiety disorders, acute and long-term treatment plans of patients with panic disorder and depression, development of novel pharmacologic agents for mood and anxiety disorders, and uses of combined cognitive-behavioral and pharmacologic therapies for treatment-refractory patients.
Publications by Dr. Worthington
Dr. Amanda Baker is a licensed psychologist in the Center for Anxiety and Traumatic Stress Disorders and Complicated Grief Program. Dr. Baker received her PhD from Boston University and completed her predoctoral internship at Mass General.
Dr. Baker's clinical and research interests involve mediators and moderators of the etiology and cognitive behavioral treatments for anxiety. She recently received a two-year grant from Harvard Catalyst/The Harvard Clinical and Translational Science Center/National Institutes of Health to study intra-individual networks of panic disorder in hopes of being able to personalize CBT treatments in the future. She has been trained in a variety of evidence-based assessment methods and cognitive behavioral therapies for anxiety, mood, OC spectrum and traumatic stress disorders, including panic disorder, generalized anxiety disorder, social anxiety disorder, posttraumatic stress disorder, depression, body dysmorphic disorder, obsessive-compulsive disorder, and tic disorders. Dr. Baker was previously awarded a Livingston Fellowship for Young Investigators from Harvard Medical School to conduct research on anxiety sensitivity and suicidality in OC spectrum and anxiety disorders. Dr. Baker is a member of the Association for Behavioral and Cognitive Therapies (ABCT), the American Psychological Association (APA) and the Association for Depression and Anxiety Disorders (ADAA).
Publications by Dr. Baker
Jonah Cohen, PhD, is an instructor at Harvard Medical School. Dr. Cohen received his PhD from Temple University and completed his predoctoral internship at Columbia University Medical Center. He went on to complete his fellowship at the University of Pennsylvania Health System.
Dr. Cohen's clinical interests includes evidence-based interventions and psychotherapy integration for various disorders, including anxiety and related disorders. He has extensive experience in cognitive behavioral, mindfulness-based, dialectical behavioral, and psychodynamic psychotherapies. Dr. Cohen's research is focused on understanding the predictors and mechanisms of treatments in an effort to improve their outcomes. He is the recipient of clinical awards from various institutions including the American Psychological Association, the Anxiety and Depression Association of America, the Beck Institute and the American Psychoanalytic Association.
Staff PsychologistStaff Psychologist, Home Base Program
Dr. Elizabeth Goetter is a clinical psychologist in the Center for Anxiety and Traumatic Stress Disorders and Complicated Grief Program and assistant in psychology at Mass General. She also serves as director of the outpatient clinic at the Red Sox Foundation/Massachusetts General Hospital Home Base Program, where she specializes in the treatment of veterans with PTSD and other deployment-related mental health concerns. Dr. Goetter received her PhD from Drexel University and completed her doctoral internship at the University of California, San Diego and San Diego VA Healthcare System.
Dr. Goetter's clinical and research interests surround the utilization of and access to empirically supported treatments for anxiety and traumatic stress disorders. Dr. Goetter has been trained in a variety of cognitive behavioral therapies for anxiety and traumatic stress disorders, including Cognitive Processing Therapy and Prolonged Exposure Therapy for PTSD. Dr. Goetter is a member of the Association for Behavioral and Cognitive Therapies (ABCT), the Anxiety and Depression Association of American (ADAA), and the Association for Contextual Behavioral Science (ACBS).
Publications by Dr. Goetter
Rachel Zack Ishikawa, PhD, is a clinical psychologist and assistant in psychology in the Center for Anxiety and Traumatic Stress Disorders and the Geriatric Psychiatry Program at Massachusetts General Hospital. Dr. Ishikawa received her PhD from Clark University and completed her postdoctoral fellowship at the Victims of Violence Program at the Cambridge Health Alliance. She holds a Master of Public Health degree in International Health from Emory University.
Dr. Ishikawa’s clinical interests include the use of empirically supported treatments for anxiety and traumatic stress disorders and strategies to improve access to care for ethnic minority groups and older adults. Dr. Ishikawa’s research has examined factors related to mental health treatment disparities among underserved populations. Dr. Ishikawa is a member of the Association for Behavioral and Cognitive Therapies (ABCT) and the American Psychological Association (APA).
Director, Anxiety and Complicated Grief Program, NYU Langone Health
Dr. Naomi M. Simon, a board-certified psychiatrist, is director of the Anxiety and Complicated Grief Program at NYU Langone Health. Dr. Simon received an MD from Harvard Medical School and completed a medical internship and residency in psychiatry at Columbia Presbyterian Hospital/New York State Psychiatric Institute where she also served as chief resident. In addition, she completed fellowship training in consultation psychiatry at Mass General and has a masters in epidemiology from the Harvard School of Public Health.
Dr. Simon’s major clinical and research interests include optimizing initial and next step psychotherapy and medication treatments for anxiety and stress related disorders, and understanding the presentation and biological impact of trauma, loss, and anxiety disorders. She has served as a principal investigator or co-investigator on numerous studies aimed at improving our understanding and treatment of post-traumatic stress disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and the syndrome of complicated grief.
Susanne S. Hoeppner, PhD, MApStat, is a biostatistician and epidemiologist at the Center for Anxiety and Traumatic Stress Disorders and Complicated Grief Program and an assistant investigator in psychology at the Mass General/Harvard Medical School. Dr. Hoeppner received her PhD in oceanography and coastal sciences and her Master in Applied Statistics from Louisiana State University and conducted three years of postdoctoral research in climate change ecology at the University of Massachusetts Boston and Purdue University. With more than 12 years of experience in research and clinical investigation, she has extensive training and expertise in experimental design, statistical analysis and simulation modeling.
Dr. Hoeppner's clinical interests are in modeling dynamic health behavior change and positive psychology. She has served as the principal statistician on pivotal trials approved by the FDA and has designed and analyzed Phase I-III studies in addiction, psychiatry, and psychology. She also has ample experience setting up, updating, and overseeing the use of electronic data capture forms as implemented via REDCap, having designed and managed such databases for several single- and multi-site clinical trials at Mass General, and routinely trains and advises research assistants, data managers, and clinical staff on principles of good clinical practice.
Publications by Dr. Hoeppner
Clinical Fellow in Psychology, Massachusetts General Hospital
Ryan Jane Jacoby, MA, is a clinical fellow in psychology completing her predoctoral internship in the Cognitive Behavioral Therapy track at Massachusetts General Hospital. Ryan attended Williams College for her bachelor’s degree in psychology. She is completing her PhD in clinical psychology in the Anxiety Lab at the University of North Carolina at Chapel Hill, where she defended her dissertation entitled, “A Translational Study of the Mechanisms of Exposure Therapy for Obsessions: Gradual vs. Variable Exposure Intensity.” Ryan’s clinical and research interests are broadly focused on the nature and treatment of OCD and anxiety disorders, including specific interests in psychological mechanisms of change in exposure-based therapy for anxiety-related problems (e.g., inhibitory learning approaches to exposure) as well as treatment augmentation strategies that capitalize on these mechanisms of action. She is also interested in transdiagnostic psychological processes (e.g., intolerance of uncertainty) as well as improving behavioral and psychophysiological measurement of these processes and therapy outcomes.
Doctoral Candidate in Clinical Psychology, Harvard University
Nicole J. LeBlanc, MA, is a clinical fellow in psychology, completing predoctoral clinical training at the Center for Anxiety and Traumatic Stress Disorders and Complicated Grief Program. She is a doctoral candidate in clinical psychology at Harvard University, where she conducts research examining the association between interpersonal factors and the development and maintenance of emotional disorders. Nicole is currently working on her dissertation, which is a study examining the efficacy of brief cognitive-behavioral interventions to reduce loneliness among young adults. Her clinical interests include empirical-supported treatments for anxiety and traumatic stress disorders. She is a member of the Association for Behavioral and Cognitive Therapies (ABCT), the Anxiety and Depression Association of American (ADAA), and the Society for a Science of Clinical Psychology (SSCP).
Donald Robinaugh is a clinical fellow in psychology (psychiatry) at Massachusetts General Hospital/Harvard Medical School. He completed his PhD in the Clinical Science program at Harvard University. Donald’s clinical training has focused on empirically supported treatments for anxiety disorders and complicated grief (CG). Donald’s research focuses on examining cognitive processes involved in the development and maintenance of emotional disorders following loss or trauma. He is currently conducting studies examining autobiographical memory and prospection deficits in CG, information processing biases in post-traumatic stress disorder (PTSD), and the association between overgeneral/abstract cognitive biases and memory deficits in CG and PTSD.
Program ManagerProgram Manager, Community Psychiatry Program for Research in Implementation and Dissemination of Evidence-Based Treatments (PRIDE)
Kaylie Patrick, MPH, serves as the program manager of both the Center for Anxiety and Traumatic Stress Disorders and Complicated Grief Program and the Community Psychiatry Program for Research in Implementation and Dissemination of Evidence-Based Treatments (PRIDE) at Mass General. She earned her MPH in epidemiology from Boston University School of Public Health and holds a BS in public health from the University at Albany.
In her role as program manager within these two research labs, Kaylie is responsible for directing the daily operations, including personnel supervision, grant management, strategic planning initiatives, and financial oversight. She is also deeply involved in ongoing research projects and oversees many of the research activities.
She is an experienced program manager having managed multiple concurrent local and international research projects. Her research interests include global research capacity building, health and human rights, racial and social justice and the dissemination and implementation of evidence-based practices in under-resourced settings. Prior to joining PRIDE, Kaylie worked at the FXB Center of Health and Human Rights at the Harvard T. H. Chan School of Public Health managing projects throughout Nepal, Hong Kong, China and Bangladesh.
Mackenzie Brown graduated from UNC-Chapel Hill in 2015 with a BA in psychology. Prior to working at CATSD, she worked as a research coordinator at the Center for Healthy Weight and Wellness at Washington University School of Medicine focusing on the treatment of childhood obesity, and was specifically interested in psychosocial factors, stigma, and bullying. Her passion for working in the field of anxiety disorders led her to pursue a position at CATSD. She is interested in the mechanisms of treatment for anxiety disorders, as well as the physiological correlates of anxiety. Mackenzie hopes to pursue a PhD in clinical psychology after her time working at CATSD.
Clinical Research Coordinator
Olivia Losiewicz graduated from Harvard College in 2018 with a BA in psychology and statistics. At Harvard, Olivia worked as a research assistant in Dr. Richard McNally’s lab on studies related to the social and behavioral factors affecting etiology and maintenance of emotional disorders. She completed a senior honors thesis titled, “The Emotional Effects of Socially Processing Political News,” in which she examined how discussing political news with a friend via technology impacted emotion regulation. Olivia’s other research interests include social, environmental, and behavioral risk factors for emotional disorders and implementation of prevention and treatment techniques. She is especially interested in the role of technology and social media in contributing to or treating psychological disorders.
At CATSD, Olivia works on studies related to transcranial light therapy, cognitive-behavioral therapy for panic disorder and a treatment evaluation for generalized anxiety.
Emma Toner graduated from Barnard College of Columbia University with a BA in psychology and sociology. While at Barnard, she completed a senior honors thesis on mental health in the LGBTQ+ community with a specific focus on psychological sequelae following identity-based trauma and discrimination. Prior to working at Mass General, she served as an undergraduate research assistant at the New York State Psychiatric Institute and the Icahn School of Medicine at Mount Sinai. At CATSD, she works as a clinical research coordinator on studies seeking to improve our understanding and treatment of anxiety and bereavement. Following her time at CATSD, Emma hopes to pursue a PhD in clinical psychology.
Meredith J. Ward graduated with institutional honors and departmental honors from Vassar College with a BA in psychological science. While at Vassar, she completed a senior honors thesis on the psychophysiological effects of a mindfulness intervention on the acute stress response, and the qualitative effects of a mindfulness intervention on quality of life and perceived stress. Prior to working at Mass General, she served as an undergraduate research assistant in the Memory Neuroscience Laboratory and the Emotions and Psychophysiology Laboratory. Currently, Meredith works on studies related to emotion perception, mindfulness and psychophysiological and gastrointestinal biomarkers of symptom severity. Meredith is interested in the role of cognition and beliefs in emotional experience, and the dissemination and implementation of evidence-based cognitive therapies for at-risk populations. She hopes to pursue a PhD after her time at CATSD to research and implement evidence-based, accessible interventions for trauma-related stress and anxiety.
The first step to participating in a research study is a brief phone interview, which will help us determine whether any of our studies might be appropriate for you. If eligible, we will invite you in for an initial screening visit.
Please call 1-866-44-WORRY (866-449-6779) for this phone interview.
The initial visit for all of our studies takes two to three hours and involves:
At this visit, our research staff will review the specific risks and benefits of participating in a study with you.
The number of visits and their specific type(s) after the initial appointment varies depending on which study you enroll in. Our studies currently range from eight weeks to six months in length. You will typically be asked to come in about once a week to meet your doctor for assessment or treatment. The length of these visits depends on the study. You may also be asked to fill out some questionnaires and have your vital signs taken to ensure that you are healthy.
We are committed to protecting your privacy. All study data will be labeled with a unique study ID code, rather than any information that could be used to identify you such as your name or date of birth. Signed consent forms and any correspondence containing your name or other identifying information is stored in a locked cabinet. At your first appointment with us, you will receive the Partners Notice for Use and Sharing of Protected Health Information, which gives more details about how your privacy is protected. The consent form for the study you participate in will also contain this information.
No. However, if you choose to enroll in a study, information from your medical records within the Partners HealthCare System that are reasonably related to the conduct and oversight of the study may be accessed during the course of the study. If health information is needed from your doctors or hospitals outside Partners, you will be asked to give permission for your medical records to be sent to us.
No, there is no cost to you or your health insurance company for you taking part in a study. Parking is available at no cost.
Evaluation and study treatments are provided at no cost. Some studies (but not all) also provide a small compensation for your time.
We ask that women who enroll in our studies do not become pregnant or breastfeed throughout the course of the study.
Our clinic primarily provides treatment through research studies. If you are interested in being seen outside of research, please call the Psychiatric Triage line: 617-724-7792.
Please note: Generally you must have a primary care physician at Mass General to be seen in the outpatient (non-research) clinics in the Psychiatry Department. If you do not have a primary care physician at Mass General, please see our list of referrals.
We only treat patients who are 18 or older. If you are under 18 or looking for treatment for your child, please call Pediatric Psychopharmacology at 617-934-4644.
One Bowdoin Square, 6th FloorBoston, MA 02114
Phone: 866-44-WORRY (866-449-6779)Email: firstname.lastname@example.org
Our center is located on the 6th floor of One Bowdoin Square (the pink granite, high-rise building next to a small public park at the intersection of Cambridge Street and New Chardon Street). We are located directly across the street from the Rite-Aid Pharmacy on Cambridge Street.
There is a free Partners HealthCare shuttle bus that runs between Mass General and North Station (where you can connect to the commuter rail and MBTA orange and green lines). Please allow 20-30 minutes for van arrival. Get more information about the shuttle bus and see the shuttle bus schedule.
The Yawkey Center garage is the closest Mass General garage to the free shuttle. After you have parked, go to the Yawkey Information Desk to ask about the shuttle bus, which picks up in front of the Yawkey Building. You can call the Mass General Transportation Office at 617-726-2250 to get more information about the shuttle.
The closest stop to our center is 25 New Chardon Street (at the traffic signal). When you get off the shuttle, walk across New Chardon Street to One Bowdoin Square.
Complicated grief (CG) has also been called "traumatic grief" or "pathological grief" at times. CG grief usually occurs after the death of a loved one. Individuals with CG may find that they are unable to accept the death and that their feelings remain strong and persistent. In addition, there may be certain types of disturbing ideas that seem to inhibit the natural process of gradual diminishing grief intensity. Another way of saying this is that grief isn't working and the bereaved person is "stuck" in the grieving process. When this happens, grief intensity remains high and adjustment does not occur.
Complicated grief is characterized by a number of symptoms that continue for six months or more after a loss:
These symptoms can cause substantial distress and have been associated with impaired quality of life, poor medical outcomes and increased rates of suicide.
Standard treatments include medications aimed at specific symptoms such as antidepressants, anti-anxiety medications, and sleep-aids. Recent studies suggest that antidepressants such as bupropion (Wellbutrin) and paroxetine (Paxil) may help relieve symptoms of CG. There is also a short-term therapy recently developed and still being studied by M. Katherine Shear, MD specifically for complicated grief called "Complicated Grief Therapy."
Use this brief questionnaire to evaluate the presence of complicated grief symptoms.
If you are interested in participating in a treatment study, please contact us.
People with generalized anxiety disorder (GAD) find it difficult to control their worry. This inability to stop worrying or to relax, even in the absence of major life stresses, is one of the cardinal features of the disorder.
Individuals with GAD also often experience a number of associated symptoms:
The anxiety and worry is considered a disorder if it is severe enough to cause an individual significant distress or interferes with social or occupational functioning. Adults with GAD often worry excessively about everyday, routine life circumstances such as possible job responsibilities, finances, or the health of family members. A number of effective treatments are available for GAD, such as anti-anxiety medication or cognitive-behavioral therapy (which reduces worry through changes in thinking and behavior patterns).
Panic disorder is characterized by recurrent unexpected panic attacks followed by at least a month of persistent concern about having more attacks, worry about the implications of having an attack (e.g., is there something wrong with my heart?) or a change in behavior related to the attacks (such as avoidance).
Panic attacks are periods of marked fear or anxiety that tend to come on quickly, peak within 10 minutes and are accompanied by distressing symptoms of arousal including:
Many patients with panic disorder develop agoraphobia, which is a concern about being in places or situations in which help or easy escape may not be available in the event of having an attack, or in which previous attacks have occurred. Some individuals with agoraphobia avoid the situations they are afraid of or require a companion to accompany them, others endure them with a great deal of distress.
Panic disorder can cause significant difficulties, including marked distress, social and job-related dysfunction, increased utilization of medical services (e.g., visits to doctors and emergency rooms) and increased rates of depression and alcohol abuse. A number of effective treatments are available, including medications such as antidepressants or benzodiazepines ("Valium-like" medications) and psychotherapies such as cognitive-behavioral therapy.
Many kinds of traumatic events can lead to the development of PTSD, such as:
Although not all individuals exposed to a trauma develop PTSD, some individuals experience a number of distressing psychological and physical symptoms including re-experiencing, avoidance or numbing and hyperarousal.
Re-experiencing symptoms include:
Avoidance and numbing symptoms include:
Hyperarousal symptoms include:
In order to receive a PTSD diagnosis, symptoms must persist for at least one month and cause significant distress, interference, or impairment in work, school, or social functioning. Symptoms may last for several months, or become even more chronic. For some, PTSD symptoms emerge six months or more after the traumatic event.
There are a number of effective medications available to treat the symptoms of PTSD, including antidepressants and some newer anti-anxiety or mood-stabilizing medications. Many individuals with PTSD do well with treatment that includes both psychotherapy and medication.
Cognitive behavioral therapy (CBT), including prolonged exposure, cognitive processing therapy and skills training in affect and interpersonal regulation, is effective for many patients with PTSD. CBT usually involves working closely with a therapist to systematically process the traumatic event, identify and modify negative thoughts that interfere with recovery from the trauma and learn to face situations or feelings associated with the trauma. In addition, CBT helps individuals learn skills for managing difficult emotions and overcoming difficulties in interpersonal relationships.
When an individual with social phobia enters or thinks about entering a feared situation, anxiety increases and for some may result in symptoms of a panic attack. Examples of feared situations include persistent fear of public speaking, meeting new people, attending parties, going to school or having social contact through a job.
Although most people have some anxiety about social and/or performance situations, these fears are more severe, persist and may limit participation in or enjoyment of every day activities for an individual with social phobia. Social anxiety symptoms may interfere with success or completion of school, making new friends, creating relationships and employment.
Nonetheless, many individuals suffer with social phobia for many years without a diagnosis or treatment. However, there are a number of effective treatments available. Options include medications such as antidepressants or benzodiazepines ("Valium-like" medications) and psychotherapy (counseling or "talk therapy"), especially cognitive behavioral therapy.
Back to Top